X4 Pharmaceuticals To Present Trial-In-Progress Poster On Phase 3 Study Of Mavorixafor In Chronic Neutropenia At 66th ASH Annual Meeting & Exposition
Benzinga Newsdesk 1 year ago
BiotechNewsGeneral
X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced its upcoming presentations at the 66th American Society of Hematology (ASH)
X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced its upcoming presentations at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, including a trial-in-progress poster on the ongoing pivotal Phase 3 clinical trial exploring the use of mavorixafor, an oral CXCR4 antagonist, for the treatment of people with chronic neutropenia (CN). The meeting will take place December 7-10, 2024, in San Diego, CA.